Publication

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis

Diabetes, Obesity and Metabolism 22(8):1328-1338, 2020

Kannt A, Nygaard Madsen A, Kammermeier C, Elvert R, Klöckener T, Bossart M, Haack T, Evers A, Lorenz K, Hennerici W, Rocher C, Böcskei Z, Guillemot JC, Mikol V, Pattou F, Staels B, Wagner M

View publication

Subjects
Therapeutic AreaMouseTargetCompoundMethod/EndpointSpeciesBody compositionAMLN DIO-MASH mouseBody weightBlood biochemistryMetabolic dysfunction-associated steatohepatitisGIP receptorGLP-1 receptorGlucagon receptorGIP receptor agonistImage analysisGLP-1 receptor agonistGlucagon receptor agonistLiver biopsyLiver morphometryReal-time food intake/activity analysisRNA sequencingLiraglutide

Share this page

Resource Library

Related resources
Publication
Mastiha (Pistacia Lentiscus) improves gut microbiota diversity, hepatic steatosis and disease activity in a biopsy-confirmed mouse model of advanced non-alcoholic steatohepatitis and fibrosis
Poster
Hepatoprotective effects of semaglutide and tirzepatide therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH 
Poster
Hepatoprotective effects of a semaglutide, elafibranor and resmetirom in the non-obese CDAA-HFD rat model of advanced MASH with progressive fibrosis
Poster
Characterization of resmetirom in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top